Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01536015
Other study ID # SP1055
Secondary ID
Status Terminated
Phase Phase 3
First received February 15, 2012
Last updated July 7, 2014
Start date January 2012
Est. completion date October 2013

Study information

Verified date July 2014
Source UCB Pharma
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The primary purpose is to demonstrate superiority of Rotigotine over Placebo on motor symptoms when used in subjects with symptoms of Gastrointestinal Dysfunction. Hypothesis: Rotigotine will decrease OFF time compared to Placebo.


Recruitment information / eligibility

Status Terminated
Enrollment 25
Est. completion date October 2013
Est. primary completion date October 2013
Accepts healthy volunteers No
Gender Both
Age group 30 Years and older
Eligibility Inclusion Criteria:

- Subject is informed and given ample time and opportunity to think about his/her participation in this study and has given his/her written informed consent on an Institutional Review Board approved consent form

- Subject is willing and able to comply with all study requirements (protocol, visit schedule, procedures, and medication application)

- Subject is male or female and = 30 years of age

- Subject has Idiopathic Parkinson's Disease of more than 3 years duration, as defined by the cardinal sign, bradykinesia, plus the presence of at least 1 of the following: resting tremor, rigidity, impairment of postural reflexes; and is without any other known or suspected cause of Parkinsonism

- Subject has a Hoehn & Yahr stage score II through IV

- Subject must be on a stable dose of L-dopa, either short-acting or sustained release (in combination with Benserazide or Carbidopa), of at least 200 mg/day administered in at least 2 intakes, for at least 21 days prior to starting Parkinson's diaries

- Subject must be able to differentiate between the "on" and "off" state (and thereby be able to recognize the Time To "On" (TTON)), and be willing and able to accurately complete a Parkinson's Disease subject diary on designated days (with assistance from caregivers, if required)

- Subject must complete 6 Parkinson's diaries over a period of 6 days, with 4 of the 6 Parkinson's diaries being "valid" as determined by the investigator. The "valid" Parkinson's diaries confirm that the subject has an average of at least 2.5 h/day spent in the "off" state

- Subject receiving a Monoamine Oxidase (MAO)-B Inhibitor (eg, Selegiline or Rasagiline), an n-Methyl-d-Aspartate Antagonist (eg, Amantadine), or allowed anti-Parkinson medications and has been on a stable dose for at least 21 days prior to starting Parkinson's diaries and is anticipated to be maintained on that dose for the duration of the study

- Subject has clinical symptoms of Gastrointestinal Dysfunction (GID) confirmed by at least 1 of the following

•Parkinson's disease-related GI symptoms as per the Gastrointestinal Degenerative Scale (GIND) Scale: defecatory dysfunction, constipation, excessive gas, abdominal pain, bloating, nausea, vomiting, anorexia, early satiety, or weight loss (except sialorrhea and dysphagia)

- Female subjects of childbearing potential must agree to use 1 of the following contraceptive methods: oral contraceptive, intrauterine device, or double-barrier method, throughout the study and for 2 weeks after the removal of study medication

Exclusion Criteria:

- Subject has previously participated in this study

- Subject has participated in another study of an investigational medicinal product (IMP) or a medical device within the last 30 days or is currently participating in another study of an IMP or a medical device

- Subject has an Atypical Parkinsonian Syndrome due to drugs (eg, Metoclopramide, Flunarizine), Metabolic Neurogenetic Disorders (eg, Wilson's Disease), Encephalitis, Cerebrovascular Disease, or Degenerative Disease (eg, Progressive Supranuclear Palsy)

- Subject has a history of Pallidotomy, Thalamotomy, Deep Brain Stimulation, or Fetal Tissue Transplant

- Subject has Dementia, Active Psychosis, or Hallucinations

- Subject exhibits Dopaminergic Dysregulation Syndrome

- Subject is receiving therapy with certain medications in a specific timeframe as specified in the protocol

- Subject has history of chronic Gastrointestinal (GI) Disease not related to Parkinson's disease which in the judgement of the investigator may affect the ability of the subject to participate in the study (ie, Irritable Bowel Syndrome, Diverticulitis, Crohn's Disease, etc) or GI/abdominal surgery (except for Appendectomy, Hysterectomy, or Cholecystectomy)

- Subject has had any GI surgery in the 3 months prior to the Screening Visit

- Subject has a current diagnosis of Epilepsy, has a history of seizures as an adult, or has a history of stroke or Transient Ischemic Attack within 1 year prior to the Screening Visit

- Subject has clinically relevant Hepatic or Renal Dysfunction

- Subject has clinically relevant Cardiac Dysfunction (any cardiac disorder that in the opinion of the investigator would put the subject at risk of clinically relevant arrhythmia)

- Subject has had a Myocardial Infarction within the last 1 year prior to the Screening Visit

- Subject has a history of Symptomatic (not Asymptomatic) Orthostatic Hypotension

- Subject has a Systolic Blood Pressure (BP) < 105 mmHg at the Screening Visit

- Subject has a history of chronic alcohol or drug abuse within the prior 6 months

- Female subject is pregnant or lactating

- Subject (male or female) is of child bearing potential but not surgically sterile or not using adequate birth control methods

- Subject has evidence of an Impulse Control Disorder according to the Modified Minnesota Impulsive Disorders Interview (mMIDI) at the Screening Visit

- Subject has a lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response ('Yes') to either Question 4 or Question 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) at the Screening Visit

- Subject has a significant skin disease/condition that would make transdermal drug use inappropriate, including a history of skin sensitivity to adhesives or other transdermal medications

- Subject has a known hypersensitivity to any components of the Rotigotine patch, including Sodium Metabisulfite

- Subject has any medical, psychiatric, or cognitive condition, or laboratory abnormality that would, in the opinion of the investigator, jeopardize or compromise the subject's well-being or ability to participate in the study

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Rotigotine
Strength and Form: 4 - 8 mg patches, one patch applied every 24 hours Dosage and Frequency: One patch every 24 hours Duration: 10 weeks
Placebo
Frequency: One patch applied every 24 hours Duration: 10 weeks

Locations

Country Name City State
United States 032 Annapolis Maryland
United States 011 Birmingham Alabama
United States 034 Charlotte North Carolina
United States 016 Commack New York
United States 031 Cordova Tennessee
United States 022 Fountain Valley California
United States 008 Gainesville Florida
United States 001 Gilbert Arizona
United States 014 Houston Texas
United States 017 Irvine California
United States 012 Kirkland Washington
United States 027 Lincoln Nebraska
United States 018 Memphis Tennessee
United States 009 Miami Florida
United States 013 Milwaukee Wisconsin
United States 026 Mineola New York
United States 010 Ormond Beach Florida
United States 028 Pasadena California
United States 002 Raleigh North Carolina
United States 030 Richmond Virginia
United States 007 Salisbury North Carolina
United States 015 Sunnyvale California
United States 006 Sunrise Florida
United States 021 Toledo Ohio
United States 023 Tulsa Oklahoma
United States 003 Virginia Beach Virginia

Sponsors (1)

Lead Sponsor Collaborator
UCB Pharma

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Rotigotine Versus Placebo in the Absolute Time Spent "Off" From Baseline to the End of the 7-week Maintenance Period Mean number of hours marked "off" during a 24-hour period. Baseline to 10 weeks No
Secondary Change in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS UPDRS) Part III (Motor Examination) in the "on" State From Baseline to the End of the 7-week Maintenance Period The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS UPDRS) Part III is an 18-item scale with each single item of the scale ranging from 0 (normal) to 4 (severe). Baseline to 10 weeks No
Secondary Change in Predictability of "Off" Time (Using MDS UPDRS Part IV Item 4.5) From Baseline to End of the 7-week Maintenance Period The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS UPDRS) Part IV is a 6-item scale with each single item of the scale ranging from 0 (normal) to 4 (severe). Baseline to 10 weeks No
Secondary Change in Score on Gastrointestinal Neurodegenerative Scale (GIND) From Baseline to the End of the of the 7-week Maintenance Period Gastrointestinal Neurodegenerative Scale (GIND) is an 18-item scale measuring gastrointestinal dysfunction with each single item of the scale ranging from 0 (never or not at all) to 5 (very severe). Baseline to 10 weeks No
Secondary Change in Score on Fatigue Severity Scale (FSS) From Baseline to the End of 7-week Maintenance Period The Fatigue Severity Scale is a 9-item scale measuring the impact of fatigue on everyday functioning (e.g. "fatigue interferes with my work, each single item of the scale ranging from 1 (disagree) to 7 (agree). Baseline to 10 weeks No
Secondary Change in Score on Parkinson's Disease Questionnaire (PDQ8) From Baseline to the End of 7-week Maintenance Period The Parkinson's Disease Questionnaire (PDQ-8) is a self-administered 8-item questionnaire that assesses issues associated with Parkinson's disease. Each single item of the 8-item questionnaire ranges from 0 (never) to 4 (always). Baseline to 10 weeks No
See also
  Status Clinical Trial Phase
Recruiting NCT02154724 - Clinical Study for Adaptive Deep Brain Stimulation (aDBS)Controlled by Intracerebral Activity in Parkinson's Disease N/A
Completed NCT02549092 - A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD) Phase 3
Completed NCT01960842 - A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian Medications Phase 3
Completed NCT01723904 - A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease Phase 3
Completed NCT01479127 - Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease Phase 2
Completed NCT03007888 - A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease Phase 2
Completed NCT00660673 - Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease Phase 3
Active, not recruiting NCT04802733 - Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease Phase 1
Completed NCT01736176 - A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's Disease Phase 3
Completed NCT02082249 - An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications Phase 3
Completed NCT02611713 - Observational Study Evaluating Long-Term Effectiveness of Duodopa/Duopa in Patients With Advanced Parkinson's Disease
Completed NCT00357994 - Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Phase 3
Completed NCT00335153 - Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease Phase 3
Active, not recruiting NCT06396494 - An Automated Navigation System for Deep Brain Electrode Implantation
Recruiting NCT06195124 - A Study on the Safety and Tolerability of RGL-193 in Patients With Advanced Parkinson's Disease Early Phase 1
Completed NCT00660387 - Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Phase 3